JP7719713B2 - α－シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法 - Google Patents

α－シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法

Info

Publication number
JP7719713B2
JP7719713B2 JP2021516452A JP2021516452A JP7719713B2 JP 7719713 B2 JP7719713 B2 JP 7719713B2 JP 2021516452 A JP2021516452 A JP 2021516452A JP 2021516452 A JP2021516452 A JP 2021516452A JP 7719713 B2 JP7719713 B2 JP 7719713B2
Authority
JP
Japan
Prior art keywords
cdr
seq
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021516452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502369A (ja
JP2022502369A5 (enExample
Inventor
アール． キャッシュマン，ニール
エス． プロトキン，スティーブン
ペン，シュビアオ
カプラン，ヨハンネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promis Neurosciences Inc
Original Assignee
Promis Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promis Neurosciences Inc filed Critical Promis Neurosciences Inc
Publication of JP2022502369A publication Critical patent/JP2022502369A/ja
Publication of JP2022502369A5 publication Critical patent/JP2022502369A5/ja
Application granted granted Critical
Publication of JP7719713B2 publication Critical patent/JP7719713B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22002—Papain (3.4.22.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2021516452A 2018-10-07 2019-10-07 α－シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法 Active JP7719713B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862742408P 2018-10-07 2018-10-07
US62/742,408 2018-10-07
US201862780599P 2018-12-17 2018-12-17
US62/780,599 2018-12-17
US201962820701P 2019-03-19 2019-03-19
US62/820,701 2019-03-19
US201962864060P 2019-06-20 2019-06-20
US62/864,060 2019-06-20
PCT/CA2019/051434 WO2020073121A1 (en) 2018-10-07 2019-10-07 Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof

Publications (3)

Publication Number Publication Date
JP2022502369A JP2022502369A (ja) 2022-01-11
JP2022502369A5 JP2022502369A5 (enExample) 2022-10-20
JP7719713B2 true JP7719713B2 (ja) 2025-08-06

Family

ID=70163645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021516452A Active JP7719713B2 (ja) 2018-10-07 2019-10-07 α－シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法

Country Status (6)

Country Link
US (2) US12404321B2 (enExample)
EP (1) EP3861015A4 (enExample)
JP (1) JP7719713B2 (enExample)
AU (1) AU2019356804B2 (enExample)
CA (1) CA3148562A1 (enExample)
WO (1) WO2020073121A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
WO2025236075A1 (en) * 2024-05-07 2025-11-20 The University Of British Columbia Immunogenic compositions for synucleinopathies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517928A (ja) 2004-10-19 2008-05-29 エラン ファーマシューティカルズ，インコーポレイテッド レヴィー小体病におけるαシヌクレインの切断断片
JP2011512363A (ja) 2008-02-22 2011-04-21 アフィリス・アクチェンゲゼルシャフト 神経変性疾患治療のためのαシヌクレインのミモトープ及びそれらのワクチン
US20110319334A1 (en) 2009-03-09 2011-12-29 Ramot At Tel-Aviv University Ltd. Compositions and methods for prevention and treatment of neurodegenerative diseases
JP2016511254A (ja) 2013-02-28 2016-04-14 ユナイテッド アラブ エミレーツ ユニバーシティＵｎｉｔｅｄ Ａｒａｂ Ｅｍｉｒａｔｅｓ Ｕｎｉｖｅｒｓｉｔｙ アルファ−シヌクレイン抗体及びその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102112488A (zh) 2008-07-01 2011-06-29 由卫生福利和体育大臣代表的荷兰王国 抗淀粉样折叠中间体的疫苗
JP2013500326A (ja) * 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用
JP6190113B2 (ja) * 2010-03-03 2017-08-30 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア オリゴマー特異アミロイドベータエピトープおよび抗体
CN102504016B (zh) * 2011-12-08 2014-05-28 清华大学 淀粉样蛋白纤维性寡聚体构象型抗原表位多肽及其应用
CA3004493A1 (en) * 2015-11-09 2017-05-18 The University Of British Columiba C-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CN109476729A (zh) * 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517928A (ja) 2004-10-19 2008-05-29 エラン ファーマシューティカルズ，インコーポレイテッド レヴィー小体病におけるαシヌクレインの切断断片
JP2011512363A (ja) 2008-02-22 2011-04-21 アフィリス・アクチェンゲゼルシャフト 神経変性疾患治療のためのαシヌクレインのミモトープ及びそれらのワクチン
US20110319334A1 (en) 2009-03-09 2011-12-29 Ramot At Tel-Aviv University Ltd. Compositions and methods for prevention and treatment of neurodegenerative diseases
JP2016511254A (ja) 2013-02-28 2016-04-14 ユナイテッド アラブ エミレーツ ユニバーシティＵｎｉｔｅｄ Ａｒａｂ Ｅｍｉｒａｔｅｓ Ｕｎｉｖｅｒｓｉｔｙ アルファ−シヌクレイン抗体及びその使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HONG, Dong-Pyo et al.，FEBS Letters，2011年02月04日，Vol. 585, Issue 3，pp. 561-566，DOI: 10.1016/j.fenslet.2011.01.009
MASUDA, Masami et al.，FEBS Letters，2009年02月18日，Vol. 583, Issue 4，pp. 787-791，DOI: 10.1016/j.febslet.2009.01.037
VAIKATH, Nishant N. et al.，Neurobiology of Disease，2015年07月，Vol. 79，pp. 81-99，DOI: 10.1016/j.nbd.2015.04.009
XU, Liang et al.，European Journal of Medicinal Chemistry，2016年10月04日，Vol. 121，pp. 841-850，DOI: 10.1016/j.ejmech.2016.01.044

Also Published As

Publication number Publication date
EP3861015A1 (en) 2021-08-11
CA3148562A1 (en) 2020-04-16
AU2019356804B2 (en) 2025-05-29
EP3861015A4 (en) 2022-11-23
WO2020073121A1 (en) 2020-04-16
US20250346655A1 (en) 2025-11-13
US20230051538A1 (en) 2023-02-16
JP2022502369A (ja) 2022-01-11
AU2019356804A1 (en) 2021-05-27
US12404321B2 (en) 2025-09-02

Similar Documents

Publication Publication Date Title
US12173055B2 (en) N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
AU2022201737B2 (en) Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
US11970522B2 (en) Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide
US20180346534A1 (en) C-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US11214613B2 (en) Epitopes in the RNA recognition motif 1 (RRM1) of TDP-43 and misfolding-selective antibodies thereto
US20250346655A1 (en) Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
JP2025146838A (ja) ミスフォールドｔｄｐ－４３に対する抗体およびその使用方法
CA3174188A1 (en) Antibodies to misfolded amyloid beta

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221007

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250306

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250725

R150 Certificate of patent or registration of utility model

Ref document number: 7719713

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150